Endomedix

Core Business and Technology Platform

Endomedix operates as a biological products company that develops a pipeline of advanced surgical products based on its "patented tunable platform technology." This platform technology is the foundation for a new generation of hemostatic agents and tissue repair devices. The technology utilizes two processed polysaccharide solutions which are designed to be simultaneously mixed and sprayed onto a bleeding surgical site. Upon application, these solutions rapidly form a robust hydrogel hemostat in situ. The base polysaccharide materials have a long history of use in FDA-regulated products, contributing to the system's biocompatibility.

The "tunable" nature of the platform is a significant market differentiator, allowing the company to modify the product's performance and features to suit various clinical indications. While initially focused on hemostasis, the long-term vision for the platform includes expanding its use to develop a series of tissue sealant, drug delivery, and tissue engineering devices.

Products and Services: PlexiClot??? Absorbable Hemostat

The first device emerging from Endomedix's proprietary platform is the PlexiClot??? Absorbable Hemostat. This product is being developed specifically for use in brain and spinal surgeries, a segment where current hemostatic products face significant safety challenges.

Product Mechanics and Clinical Advantages

The PlexiClot??? hemostat is designed to achieve rapid, stable hemostasis through a synergistic effect of multiple product features protected by the company???s extensive patent portfolio. Its mechanism of action collects, aggregates, and concentrates platelets to promote fast and stable clot formation.

The primary, and most critical, competitive advantage of PlexiClot??? in the neurosurgical field is its unique behavior upon fluid absorption:

• Absence of Swelling (Mass Effect): Unlike many commercially available hemostats used in these delicate surgeries, which can swell substantially (sometimes up to 45 times their original weight) as they absorb blood and body fluids, the PlexiClot??? hemostat does not swell. This proprietary characteristic is key, as current products carry mandated warnings about swelling, which can lead to mass effects and compression of sensitive neural tissues, potentially causing pain, paresis, or paralysis. Endomedix's technology is engineered to gently contract upon application, representing a major safety advancement for brain and spinal indications.
• Fast Action: In vivo trials have indicated that the Endomedix technology can be an effective hemostat in less than 30 seconds.
• Biocompatibility and Elimination: The hydrogel hemostats are designed to be left in place post-surgery, where they degrade enzymatically and are safely eliminated via the kidneys.
• Versatility: The technology is being developed for use in both open surgery and Minimally Invasive Surgery (MIS) procedures, and the underlying chemistry can be adapted for future formulations that may incorporate drug-delivery capabilities.

Market Strategy

Endomedix is targeting the large addressable market for hemostasis in brain and spinal surgeries, aiming to be the first product specifically indicated by the FDA for brain surgery, establishing a "first-in-class" market position. The company's strategy is to leverage the unparalleled safety profile and fast-acting efficacy of PlexiClot??? to capture a significant share of this high-value biosurgery segment. The platform technology is also being strategically positioned for application in military and first responder uses due to its rapid hemostasis capabilities.